Barinthus Biotherapeutics acquired by Beacon Topco; ADS delisted from Nasdaq

Barinthus Biotherapeutics plc.

Scheme of Arrangement effective Sept 9, 2026; Topco acquired all issued Barinthus shares, company now wholly-owned subsidiary.
Each Company Share/ADS exchanged for 0.111 Topco common shares; fractional entitlements cashed out.
ADS trading on Nasdaq suspended before open Sept 9, 2026; Form 25 and Form 15 to be filed to delist and suspend reporting.
Outstanding Company Options and RSUs assumed by Topco and converted into rights over Topco common stock.
Deposit Agreement with BNY Mellon terminated; shareholders' rights ceased except consideration under Merger Agreement.

item 1.02 item 2.01 item 3.01 item 3.03 item 5.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.